Press Release: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 18,300 stock options, were approved by the Compensation Committee of Aura's Board of Directors and are an incentive for them to join the company. The options vest over four years, with a 12-month cliff.
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules.
Aura Biosciences has granted inducement equity awards, including stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs), to its new CEO and President, Natalie Holles. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are tied to Ms. Holles' continued service and performance milestones. The grants aim to incentivize Ms. Holles and support Aura's strategy to strengthen leadership as it advances its clinical-stage therapies for solid tumors.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards for its new CEO and President, Natalie Holles, consisting of stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs). These awards, approved by the Board in accordance with Nasdaq rules, are tied to continuous service and, for PRSUs, achievement of performance conditions. The company is a clinical-stage biotechnology firm developing precision therapies for solid tumors.
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles
Aura Biosciences director and officer Natalie C. Holles received substantial equity awards, including 553,844 restricted stock units (RSUs), 600,118 performance RSUs, and a stock option for 2,169,103 shares, all structured as Inducement Awards. These awards are tied to multi-year vesting schedules and continued service with the company, with specific dates for vesting commencements and an exercise price of $7.3900 for the stock option. Following these grants, Holles directly owns 1,153,962 shares of common stock.
New Aura Biosciences CEO awarded options on 2.17M shares at $7.39
Aura Biosciences (NASDAQ: AURA) has granted inducement equity awards to its new CEO and President, Natalie Holles, consisting of stock options for 2,169,103 shares at an exercise price of $7.39, 600,118 RSUs, and 553,844 PRSUs. These awards are subject to multi-year time-based and, for PRSUs, performance-based vesting conditions. The grants were approved under Nasdaq Listing Rule 5635(c)(4) and align the CEO's compensation with long-term share performance, though they also introduce potential dilution.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Inc. announced its senior management will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. The company, a clinical-stage biotechnology firm, is developing precision therapies for solid tumors, with its lead candidate bel-sar (AU-011) in late-stage development for early choroidal melanoma. Webcasts of the fireside chats will be available on their investor relations website.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. Members of its senior management team will present at these events, with webcasts available on the company's website. The company is developing precision therapies for solid tumors, including its lead candidate bel-sar for choroidal melanoma and bladder cancer.
[SCHEDULE 13G] Aura Biosciences, Inc. Passive Investment Disclosure (>5%)
This SCHEDULE 13G filing indicates a passive investment disclosure for Aura Biosciences, Inc. by TCG Crossover entities and Chen Yu, collectively holding over 5% of the company's common stock. The filing details the beneficial ownership, voting, and dispositive powers of TCG Crossover GP II, TCG Crossover Fund II, TCG Crossover GP III, TCG Crossover Fund III, and Chen Yu. The reported ownership percentages are based on 96,255,907 shares of Common Stock outstanding as of May 5, 2026, and exclude shares subject to Pre-Funded Warrants due to beneficial ownership limitations.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its senior management will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. The company will host fireside chats at both events, with live webcasts available for investors. Aura Biosciences is developing precision therapies for solid tumors, including bel-sar (AU-011) for choroidal melanoma and other oncology indications.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. Members of their senior management team will hold fireside chats at both events. The webcasts will be available on the company’s website.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced that members of its senior management team will participate in upcoming investor conferences. The company specializes in developing precision therapies for solid tumors aimed at preserving organ function. The announcement was made on May 12, 2026, and further details can be found on globenewswire.com.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences announced its Q1 2026 financial results and key business advancements, including progress in its Phase 3 CoMpass trial for early choroidal melanoma, which is expected to complete enrollment by mid-2026 and report topline data in H2 2027. The company also appointed Natalie Holles as its new CEO and strengthened its balance sheet with a $299 million equity financing, extending its cash runway into the second half of 2028. Additionally, Aura provided updates on its clinical trials for metastases to the choroid, ocular surface cancers, and bladder cancer, with early data expected throughout 2026.
Aura Biosciences raises $299M, tests vision-preserving eye cancer drug
Aura Biosciences announced its Q1 2026 financial results, highlighted by an oversubscribed equity offering that raised $280.8 million in net proceeds, extending its cash runway into the second half of 2028. The company is advancing its Phase 3 CoMpass trial for early choroidal melanoma, with enrollment expected to complete by mid-2026 and topline data anticipated in Q2 2027. Natalie Holles was also appointed as the new CEO and President.
Aura Biosciences (NASDAQ: AURA) details $299M raise, cash runway and Phase 3 plans
Aura Biosciences announced a net loss of $33.7 million for Q1 2026, alongside a successful oversubscribed $299 million equity financing which extended their cash runway into the second half of 2028. The company is advancing its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in Q2 2027, and is also progressing other clinical programs in ocular and bladder cancers. Natalie Holles has been appointed as the new CEO and President, succeeding founder Elisabet de los Pinos.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences announced its first-quarter 2026 financial results and business updates, highlighting significant progress in its clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma, which is nearing enrollment completion with topline data expected in mid-2027. The company also reported a strengthened financial position after an oversubscribed $299 million equity financing, extending its cash runway into the second half of 2028. Additionally, Natalie Holles was appointed as the new CEO and President.
Aura Biosciences, Inc. Common Stock (AURA) Stock Price Today & Analysis
This article provides an analysis of Aura Biosciences, Inc. (AURA) stock, including its current price, fundamental financials, and corporate actions. It details the company's clinical-stage biotechnology focus on developing precision immunotherapies for solid tumors, particularly its lead candidate bel-sar for choroidal melanoma. The piece also includes an FAQ for potential investors on how to buy AURA stock via the Gotrade app, minimum investment, dividend policy, and safety.
Aura Biosciences (AURA) insider Natalie Holles files initial Form 3
Aura Biosciences (AURA) has reported that insider Natalie C. Holles, identified as a director and officer (Chief Executive Officer and President), filed an initial Form 3. This filing indicates no reported share purchases, sales, gifts, or option exercises, with all transaction counts and net share changes at zero. Form 3 is an initial statement of beneficial ownership required when an individual becomes an insider, providing an opening inventory of their holdings.
Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore
Aura Biosciences has successfully priced an equity offering, netting $280.8 million. The offering, underwritten by Leerink Partners, TD Securities (USA), and Evercore Group, involved 39,591,000 common shares and 3,800,000 pre-funded warrants. The proceeds will be used to advance clinical programs, including bel-sar, for general corporate purposes, and to repurchase shares from Matrix.
Aura Biosciences closes $299.4 million public offering
Aura Biosciences (NASDAQ:AURA) has successfully closed a public offering, raising approximately $299.4 million. The clinical-stage biotechnology company sold common stock and pre-funded warrants, with proceeds aimed at advancing its pipeline, including its lead candidate bel-sar for solid tumors. Despite the stock trading near its 52-week high, InvestingPro analysis suggests it may be overvalued, although it maintains a strong cash-to-debt position.
Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buyback
Aura Biosciences successfully completed an underwritten public offering, raising approximately $280.8 million in net proceeds through the sale of common shares and pre-funded warrants. The company plans to allocate $241.8 million to advance its clinical programs, including bel-sar for choroidal melanoma, and general corporate purposes. Additionally, $39.0 million will be used to repurchase shares from Matrix Capital Management Master Fund, LP, extending Aura Bioscience's cash runway into the second half of 2028.
Aura Biosciences Announces Closing of $299 Million Public
Aura Biosciences, Inc. announced the closing of its $299 million public offering. The offering included common stock and pre-funded warrants, with the underwriters fully exercising their option to purchase additional shares. The proceeds will support the clinical-stage biotechnology company's development of precision therapies for solid tumors.
Aura raises $299M as underwriters take full extra-share option
Aura Biosciences announced the closing of its public offering, raising approximately $299.4 million in gross proceeds. This includes the sale of over 46 million common shares and 3.8 million pre-funded warrants, with underwriters fully exercising their option for additional shares. The financing will support the company's clinical programs, particularly the late-stage development of bel-sar.
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aura Biosciences, Inc. (Nasdaq: AURA) announced the closing of its underwritten public offering, which generated gross proceeds of approximately $299.4 million. The offering included the sale of common stock and pre-funded warrants, with the underwriters fully exercising their option to purchase additional shares. Aura is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors.
Aura Biosciences (NASDAQ: AURA) offers 39.6M shares, repurchase $39M
Aura Biosciences (NASDAQ: AURA) is offering 39.6 million shares of common stock and pre-funded warrants to purchase up to 3.8 million additional shares at a public offering price of $6.00 per share (with pre-funded warrants priced at $5.99999). The company expects net proceeds of approximately $244.1 million, of which $39.0 million will be used to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP, and the remaining $205.1 million will advance clinical programs for bel-sar. Aura Biosciences also provided an update on its Phase 3 CoMpass trial for bel-sar, noting that enrollment is nearing completion by mid-2026, with topline data anticipated in the second half of 2027.
Occam Global Recruits CEO for Aura Biosciences
Occam Global has appointed Natalie Holles as the new CEO of Aura Biosciences, a NASDAQ-traded clinical-stage biotechnology company. Holles, who has extensive experience in corporate strategy, operations, and commercialization, will succeed founder Elisabet de los Pinos. She will lead Aura through its next growth phase, focusing on completing a Phase 3 trial and preparing for the potential commercial launch of bel-sar, a targeted therapy for solid tumors.
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences announced the appointment of Natalie Holles as its new CEO and President, effective April 30, 2026. She succeeds founder Elisabet de los Pinos, Ph.D. The company also reported that its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma is nearing enrollment completion, with 86 patients already enrolled and more expected by May 2026, reiterating guidance for topline data in the second half of 2027.
Press Release: Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences announced a CEO transition, with Elisabet de los Pinos stepping down and Darcy Forman being appointed as interim CEO. The change comes as the company focuses on completing enrollment for its Phase 3 CoMpass trial for belzupacap sarolubicin (AU-011) in choroidal melanoma and preparing for regulatory submissions and commercialization. The company also reported strong financial results for the first quarter of 2026.
Aura Biosciences (NASDAQ: AURA) plans 6.9M-share Matrix buyback
Aura Biosciences plans to repurchase up to 6.9 million shares from Matrix Capital Management Master Fund at $5.64 per share. This transaction, contingent on the successful closing of a separate equity offering, aims to use proceeds exceeding $200 million from that offering to fund the buyback. Matrix Capital currently holds approximately 10.8% of Aura's outstanding common stock, and the repurchase is part of a larger financial strategy.
Aura Biosciences names Natalie Holles as new CEO By Investing.com
Aura Biosciences has appointed Natalie Holles as its new CEO and President, succeeding founder Elisabet de los Pinos. Holles brings extensive executive leadership experience from Third Harmonic Bio, Audentes Therapeutics, Hyperion Therapeutics, and KAI Pharmaceuticals. The company also announced nearing completion of enrollment for its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in H2 2027.
Aura Biosciences launches public offering of common stock By Investing.com
Aura Biosciences (NASDAQ:AURA) has announced a public offering of common stock and pre-funded warrants to raise capital for its late-stage pipeline. The clinical-stage biotech company, valued at $450 million, plans to grant underwriters a 30-day option for additional shares and has Leerink Partners, TD Cowen, and Evercore ISI as joint bookrunning managers. This move follows recent positive developments, including a new CEO appointment and reiterated Buy ratings from analysts with price targets up to $26, despite the company's ongoing losses.
Aura Biosciences Appoints Natalie Holles CEO as Phase 3 Trial Nears Enrollment Completion
Aura Biosciences has appointed Natalie Holles as its new CEO and president, effective April 30, 2026, as the company's Phase 3 CoMpass trial for its lead investigational therapy for early choroidal melanoma approaches enrollment completion. Holles brings over 25 years of biotech experience, including corporate strategy, operations, and commercialization, positioning her to lead Aura through its next growth phase, including potential commercialization. The company anticipates completing trial enrollment by mid-2026, with topline data expected in the second half of 2027.
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences announced the pricing of a $260.3 million public offering, including common stock and pre-funded warrants. The company plans to use the net proceeds to advance its clinical programs, particularly for early choroidal melanoma and registration-enabling activities for bel-sar, and for general corporate purposes. A portion of the proceeds will also be used to repurchase shares from its stockholder, Matrix Capital Management Master Fund, LP.
Aura Biosciences announces pricing of $260 million public offering of common stock and pre-funded warrants
Aura Biosciences has announced the pricing of a $260 million public offering, which includes both common stock and pre-funded warrants. The article also provides an overview of Aura Biosciences, detailing its focus on developing precision immunotherapies for solid tumors, with its lead candidate, bel-sar, currently in late-stage clinical development for choroidal melanoma and early-stage development for bladder cancer.
New Aura CEO arrives as eye cancer trial nears enrollment completion
Aura Biosciences has appointed Natalie Holles as its new CEO, President, and board member. The company also announced that its Phase 3 CoMpass trial for belzupacap sarotalocan, a treatment for early choroidal melanoma, is nearing enrollment completion, with 86 patients already enrolled and over 25 more identified for screening. Aura expects to complete enrollment by mid-2026 and release topline data in the second half of 2027.
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences has announced a change in leadership, appointing Natalie Holles as the new CEO, President, and board member, succeeding founder Dr. Elisabet de los Pinos. This transition comes as the company's Phase 3 CoMpass trial for its investigational candidate belzupacap sarotalocan (bel-sar) is nearing enrollment completion, with 86 patients already enrolled and more identified for screening. Aura Biosciences reiterates its projection for enrollment completion by mid-2026 and expects topline data from the trial in the second half of 2027.
New Aura Biosciences (NASDAQ: AURA) CEO as Phase 3 CoMpass trial nears enrollment
Aura Biosciences (NASDAQ: AURA) has appointed Natalie Holles as its new CEO and President, replacing founder Elisabet de los Pinos. This leadership change occurs as the company's Phase 3 CoMpass trial for belzupacap sarotalocan in early choroidal melanoma is nearing enrollment completion, with 86 patients already enrolled and over 25 more identified. Additionally, Aura Biosciences terminated its at-the-market share program after raising approximately $6.7 million.
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences announced the pricing of a $260 million public offering, consisting of common stock and pre-funded warrants. The company plans to use the net proceeds to advance its clinical programs, including for choroidal melanoma, and to repurchase shares from its stockholder, Matrix Capital Management Master Fund, LP. Leerink Partners, TD Cowen, Evercore ISI, LifeSci Capital, and Citizens Capital Markets are managing the offering.
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences, Inc. (Nasdaq: AURA), a clinical-stage biotechnology company, has launched an underwritten public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. Leerink Partners, TD Cowen, Evercore ISI, LifeSci Capital, and Citizens Capital Markets are managing the offering.
[ARS] Aura Biosciences, Inc. SEC Filing
This article announces an SEC filing by Aura Biosciences, Inc. (AURA) of Form ARS. The filing, accepted on April 20, 2026, is available as a PDF document on the SEC EDGAR database. It also provides an overview of Aura Biosciences, including its market cap, industry, and recent news and SEC filings.
Aura Biosciences (NASDAQ: AURA) outlines 2026 vote on directors and auditor
Aura Biosciences (NASDAQ: AURA) has announced its virtual 2026 annual shareholder meeting on June 11, 2026. Stockholders will vote to re-elect two Class II directors, Teresa Marie Bitetti and David Johnson, for terms ending in 2029, and to ratify Ernst & Young LLP as the independent auditor for 2026. The proxy statement also details 2025 executive compensation, with CEO Elisabet de los Pinos receiving approximately $3.96 million.
(AURA) as a Liquidity Pulse for Institutional Tactics
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide institutional trading strategies. It highlights strong near and mid-term sentiment, but notes elevated downside risk as long-term support signals are absent. The analysis includes position trading, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss levels.
Top Aura Biosciences Insider Makes Notable Move With Fresh Stock Sale
Aura Biosciences Inc. (AURA) CLO and Secretary, Conor Kilroy, recently sold 11,738 shares worth $82,400. This insider sale comes as the company faces tempered sentiment due to widening losses and increased R&D spending, despite a strengthened cash runway and accelerating clinical momentum. Spark, TipRanks’ AI Analyst, rates AURA as Neutral due to pre-revenue financial performance and limited valuation support.
Insider sale: Aura Biosciences (NASDAQ: AURA) reports 12,079-share sale
Aura Biosciences (NASDAQ: AURA) has reported an insider sale of 12,079 shares of Common Stock on February 17, 2026, by Conor Kilroy, generating proceeds of $61,037.31. The filing also disclosed a restricted stock unit award of 24,000 units granted on April 2, 2024, and indicated 64,150,468 shares outstanding as of April 16, 2026. The transaction is detailed in a Form 144 SEC filing.
Aura Biosciences (AURA) insider’s RSU tax sale covers 11,738 shares at ~$7
Aura Biosciences insider Conor Kilroy sold 11,738 shares of common stock at a weighted average price of approximately $7.02 per share. This sale was automatically executed to cover tax withholding obligations associated with vested restricted stock units and was not a discretionary transaction. Following the sale, Kilroy still directly holds 217,835 shares, indicating a routine tax-related disposition rather than a change in his core ownership position.
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know
Aura Biosciences (AURA) has received a Strong Buy consensus rating from Wall Street analysts, with an average price target indicating a potential 201.49% upside. This optimistic outlook is based on four recent analyst ratings. Investors are encouraged to consider the strong ratings but also to conduct their own due diligence.
Aura Biosciences, Inc. (AURA) just flashed golden cross signal: Do you buy?
The article discusses how Aura Biosciences (AURA) recently experienced a "golden cross" technical indicator. This occurs when the 50-day moving average crosses above the 200-day moving average, often signaling a potential bullish trend. Investors use such signals to inform their buying decisions, with a golden cross generally viewed as a positive sign for a stock's future performance.
Aura Biosciences, Inc. (AURA) Recently Triggered a Golden Cross Signal: Is It Time to Invest?
Aura Biosciences (AURA) has recently displayed a "golden cross" technical signal, where its 50-day moving average crossed above its 200-day moving average, often indicating a bullish trend. This, combined with a 14% share price increase over the past month, a Zacks Rank #2 (Buy) rating, and positive analyst earnings revisions, suggests potential for further gains. Investors are encouraged to monitor AURA given these technical and fundamental indicators.
Aura Biosciences, Inc. (AURA) Recently Triggered a Golden Cross Signal: Is It Time to Invest?
Aura Biosciences (AURA) has recently experienced a "golden cross" pattern, where its 50-day simple moving average crossed above its 200-day simple moving average, signaling a potential bullish trend. This technical indicator, combined with a 14% share price climb over the past month and a #2 (Buy) rating from Zacks Rank, suggests a positive outlook for the company. Analysts have also provided favorable earnings projections, making AURA an interesting stock for investors to monitor.
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Aura Biosciences, Inc. (AURA) has recently registered a "golden cross" signal, where its 50-day simple moving average crossed above its 200-day simple moving average, indicating a potential bullish breakout. The company also shows positive momentum with a 14% increase in the last four weeks and a #2 (Buy) rating on the Zacks Rank, supported by positive earnings outlook and upward revisions from analysts. Investors might consider AURA for potential near-term gains due to these technical and fundamental indicators.
AURA Should I Buy
Intellectia AI recommends a "Hold" for Aura Biosciences Inc (AURA) for beginner, long-term investors, despite some bullish technical indicators. This recommendation is due to the company's lack of positive financial performance, insider selling, and the absence of significant news or catalysts. While hedge funds are increasing positions, the core financials and EPS show no growth.
